Related Experiment Video
Updated: Aug 11, 2026
Accurate and Simple Measurement of the Pro-inflammatory Cytokine IL-1β using a Whole Blood Stimulation Assay
Published on: March 2, 2011
Immunoreactive interleukin-6 in serum of patients with B-lymphoproliferative diseases
T Pettersson1, K Metsärinne, A M Teppo
1Fourth Department of Medicine, Helsinki University Central Hospital, Finland.
Insights
Serum interleukin-6 (IL-6) levels were higher in patients with benign hypergammaglobulinaemic conditions like monoclonal gammapathy of undetermined significance (MGUS) and Sjögren's syndrome (SS) compared to healthy controls and those with B-cell malignancies.
Area of Science:
- Immunology
- Oncology
- Clinical Medicine
Background:
- Interleukin-6 (IL-6) is a cytokine involved in immune responses and inflammation.
- Elevated IL-6 levels are implicated in various hematological and autoimmune disorders.
- Understanding IL-6 dynamics is crucial for differentiating benign from malignant conditions.
Purpose of the Study:
- To compare serum immunoreactive interleukin-6 (ir-IL-6) concentrations across different patient groups and healthy controls.
- To investigate the potential of ir-IL-6 as a biomarker in benign hypergammaglobulinaemic states versus B-cell malignancies.
- To explore longitudinal changes in ir-IL-6 levels in multiple myeloma.
Main Methods:
- Radioimmunoassay was used to quantify serum ir-IL-6 levels.
- Study included patients with chronic lymphocytic leukemia (CLL), multiple myeloma (MM), monoclonal gammapathy of undetermined significance (MGUS), primary Sjögren's syndrome (SS), and healthy controls.
- Longitudinal monitoring of ir-IL-6 was performed in a subset of MM patients.
Main Results:
- All subjects had detectable ir-IL-6 levels.
- Patients with MGUS and SS exhibited significantly higher serum ir-IL-6 concentrations compared to controls.
- Patients with CLL and MM showed ir-IL-6 levels comparable to controls, and lower than MGUS and SS patients.
- Longitudinal MM studies revealed fluctuating ir-IL-6 levels around remission and relapse, without a consistent pattern.
Conclusions:
- Serum ir-IL-6 levels are elevated in benign hypergammaglobulinaemic states (MGUS, SS) compared to malignant B-cell disorders (CLL, MM).
- These findings suggest ir-IL-6 may help distinguish between benign and malignant hypergammaglobulinaemic conditions.
- Further research is needed to clarify the role of IL-6 in the pathogenesis and monitoring of these diseases.
Abstract:
Serum immunoreactive interleukin-6 (ir-IL-6) concentration was measured by radioimmunoassay in nine patients with chronic lymphocytic leukaemia (CLL), 16 patients with multiple myeloma (MM), 12 patients with monoclonal gammapathy of undetermined significance (MGUS), 22 patients with primary Sjögren's syndrome (SS), and in 32 control subjects. Measurable quantities of ir-IL-6 were detected in every sample studied. Patients with MGUS and SS had significantly higher serum ir-IL-6 (mean +/- SD) concentrations (337 +/- 92 ng l-1 and 299 +/- 100 ng l-1, respectively) than controls (92 +/- 77 ng l-1) and patients with CLL and MM (120 +/- 32 ng l-1 and 113 +/- 58 ng l-1, respectively). Longitudinal studies of ir-IL-6 concentration in a few patients with MM showed a decrease before remission and an increase prior to relapse, but no consistent pattern was detected. In conclusion, we found that serum ir-IL-6 levels are higher in patients with benign hypergammaglobulinaemic states than in patients with malignant neoplastic B-cell disorders.
